Bladder cancer is one of the most prevalent cancers worldwide.
Early detection of bladder tumors is critical for improved patient outcomes. The standard method for detection and surveillance of bladder tumors is cystoscopy with urinary cytology. Limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. Ideally, such assays would be applicable to noninvasively obtained, voided urine, and be designed not only for diagnosis, but also for monitoring disease recurrence and response to therapy. Consequently, the development of a noninvasive urine-based assay would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine-based biomarkers reported in the literature. In addition, some new technologies that have been used to identify novel urinary biomarkers are highlighted.
Written by:
Rosser CJ, Urquidi V, Goodison S. Are you the author?
Department of Urology, University of Central Florida College of Medicine, Orlando, FL 32527, USA.
Reference: Biomark Med. 2013 Oct;7(5):779-90.
doi: 10.2217/bmm.13.73
PubMed Abstract
PMID: 24044570
UroToday.com Bladder Cancer Section
